Legal entity
Every one of those 2 sits in a single category, regulation. Of the tracked stories, 1 of 2 also mention Brookings Institution, the most common co-covered peer. Across a 150-day span, the pace is roughly 0.1 stories per week. Each story carries 2.5 original sources on average, compared with 3.4 for the broader beat in this window.
Last mentioned: Aug 15, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, regulation. Of the tracked stories, 1 of 2 also mention Brookings Institution, the most common co-covered peer. Across a 150-day span, the pace is roughly 0.1 stories per week. Each story carries 2.5 original sources on average, compared with 3.4 for the broader beat in this window. At 7, the average consequence score sits above the same-window beat average of 6.3. We currently track 2 Legal stories that mention John Moolenaar, published between March 19, 2026 and August 15, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 1095 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering John Moolenaar. Shared-story counts are live from our verified record — not editorial picks.
The congressional investigation into Harvard's alleged use of Harvard Global to circumvent foreign-funding disclosure requirements carries significant regulatory and legal implications. Compliance teams, higher-ed counsel, and RegTech vendors should parse the committees' allegations for emerging enforcement priorities under Section 117.
The House Select Committee on China has raised alarms over the United States' increasing reliance on Chinese-made active pharmaceutical ingredients and biotech innovation. Lawmakers argue that Beijing is applying a proven industrial playbook to dominate the global medicine supply chain, posing significant national security and regulatory challenges.
Source: Lucy Quaggin (cn) · Lucy Quaggin (hk)
John Moolenaar is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
